ofloxacin has been researched along with Drop Attack in 2 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Periodic and continuous ECGs were recorded before and after subjects were dosed with placebo and increasing doses of levofloxacin (500 mg, 1000 mg, 1500 mg) that included doses twice the maximum recommended dose of 750 mg in a double-blind, randomized, four-period, four-sequence crossover trial." | 2.71 | Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. ( Chien, S; Goodman, DB; Natarajan, J; Noel, GJ; Padmanabhan, M; Solanki, B, 2004) |
| "Polymorphic ventricular tachycardia (PVT) is a form of ventricular tachycardia characterized by QRS complexes that seem to change direction during the tachycardia." | 1.31 | Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. ( Mousavi, MS; O'Donoghue, S; Paltoo, B, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noel, GJ | 1 |
| Goodman, DB | 1 |
| Chien, S | 1 |
| Solanki, B | 1 |
| Padmanabhan, M | 1 |
| Natarajan, J | 1 |
| Paltoo, B | 1 |
| O'Donoghue, S | 1 |
| Mousavi, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ofloxacin and Drop Attack
| Article | Year |
|---|---|
Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Cross-Over Studies; Dizziness; Dose-Response Re | 2004 |
1 other study available for ofloxacin and Drop Attack
| Article | Year |
|---|---|
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.
Topics: Anti-Infective Agents, Urinary; Electrocardiography; Female; Humans; Levofloxacin; Middle Aged; Oflo | 2001 |